Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 7/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PTGIR | P43119 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11006075 | 1.00 | TBXAS1 (1.00) | TBXAS1CYP11B2FABP4FABP5MAPT | |
| SCHEMBL11009473 | 1.00 | TBXAS1 (1.00) | TBXAS1CYP11B2FABP4FABP5MAPT | |
| SCHEMBL11007597 | 0.99 | TBXAS1 (1.00) | TBXAS1CYP11B2FABP4FABP5MAPT | |
| SCHEMBL11009385 | 0.91 | TBXAS1 (0.85) | TBXAS1CYP11B2FABP4FABP5MAPT | |
| SCHEMBL11067365 | 0.89 | TBXAS1 (0.79) | TBXAS1CYP11B2MAPT | |
| SCHEMBL11010003 | 0.89 | TBXAS1 (0.79) | TBXAS1CYP11B2MAPT | |
| SCHEMBL11068112 | 0.89 | TBXAS1 (0.79) | TBXAS1CYP11B2MAPT | |
| Hydrochloric Acid SCHEMBL7829663 | 0.88 | TBXAS1 (0.78) | TBXAS1CYP11B2 | |
| SCHEMBL11074372 | 0.88 | TBXAS1 (0.78) | TBXAS1CYP11B2ALDH1A1 | |
| SCHEMBL11006110 | 0.88 | TBXAS1 (0.78) | TBXAS1CYP11B2FABP4FABP5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242068-A4 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | NITROMED INC (US) | 2007-04-25 | — | — | EP | claimed |
| US-20030050305-A1 | Thromboxane inhibitors, compositions and methods of use | NITROMED, INC. | 2003-03-13 | — | — | US | claimed |
| EP-1242068-A1 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | Nitromed, Inc. (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001089519-A1 | THROMBOXANE INHIBITORS, COMPOSITIONS AND METHODS OF USE RELATED APPLICATIONS | NITROMED, INC. (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001032167-A1 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | NITROMED, INC. (US) | 2001-05-10 | — | — | WO | claimed |
| EP-0449764-A2 | A method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor and/or thromboxane receptor antagonist | CIBA-GEIGY AG (CH) | 1991-10-02 | — | — | EP | claimed |
| US-5021448-A | Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist | CIBA-GEIGY CORPORATION (US) | 1991-06-04 | — | — | US | claimed |
| US-4962105-A | SELECTED FROM BENAZEPRIL, BENAZEPRILAT, AND LIBENZAPRIL, BY ADMINISTERING IN COMBINATION SPECIFIC PYRIDYL INDOLE DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1990-10-09 | — | — | US | claimed |
| US-4925869-A | REACTIVATING ENZYME ACETYLCHOLINESTERASE INHIBITED BY LETHAL DOSE OF SOMAN | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-15 | — | — | US | claimed |
| US-4908380-A | Substituted 1,3-dioxane ether derivative; thromboxane A2 inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-03-13 | — | — | US | claimed |
| EP-0300675-A2 | Method for the improvement of cyclosporine therapy | MERCK FROSST CANADA INC. (CA) | 1989-01-25 | — | — | EP | claimed |
| EP-0080154-B1 | N-SUBSTITUTED 2-PYRIDYL INDOLES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR THERAPEUTICAL USE | CIBA-GEIGY AG (CH) | 1985-08-28 | — | — | EP | claimed |
| US-4478842-A | THROMBOXANE SYNTHETASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1984-10-23 | — | — | US | claimed |
| EP-0080154-A2 | N-substituted 2-pyridyl indoles, process for their preparation, pharmaceutical compositions containing them, and their therapeutical use | CIBA-GEIGY AG (CH) | 1983-06-01 | — | — | EP | claimed |
| US-9834820-B2 | Methods for the treatment and diagnosis of bone mineral density related diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-12-05 | — | — | US | disclosed |
| EP-2227560-B1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | INSERM - INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2017-10-18 | — | — | EP | disclosed |
| US-20150104437-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | Universite De Paris (FR) | 2015-04-16 | — | — | US | disclosed |
| US-4478842-A | THROMBOXANE SYNTHETASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1984-10-23 | — | — | US | disclosed |
| US-4460777-A | THROMBOXANE SYNTHETASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1984-07-17 | — | — | US | disclosed |
| EP-0080154-A2 | N-substituted 2-pyridyl indoles, process for their preparation, pharmaceutical compositions containing them, and their therapeutical use | CIBA-GEIGY AG (CH) | 1983-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104437-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | TBXAS1, TBXA2R, HPGDS | TBXAS1 1/4885CYP11B2 1077/4885FABP4 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.